Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SARS-CoV-2 Spike Glycoprotein (Omicron Variant) (Spike (Omicron))
- Target
- Spike (Omicron)
- Molecular classification
- Viral protein, Glycoprotein, Fusion protein, Receptor ligand
01
Overview
The SARS-CoV-2 spike glycoprotein is a large, trimeric, class I fusion protein found on the surface of the virus that mediates viral entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor and facilitating membrane fusion. The Omicron variant's spike protein has a high number of mutations compared to previous variants. These mutations remodel both the N-terminal domain (NTD) and receptor-binding domain (RBD), altering antigenic surfaces. Structural changes confer resistance to neutralizing antibodies and it requires higher levels of ACE2 for efficient membrane fusion.
- Other names
- SARS-CoV-2 Spike protein (Omicron)Spike glycoprotein (Omicron)S protein (Omicron)
02
Mechanism of action
Target for neutralizing antibodies; mediates viral entry via ACE2 binding and membrane fusion.
03
Biological functions
Receptor bindingMembrane fusionViral entryImmune evasion
04
Disease associations
InfectionCOVID-19 pathogenesisVascular remodelingHypertension
05
Safety considerations
Antibody-dependent enhancement (ADE)Potential for off-target effects of Spike-targeting therapeuticsEvasion of existing immunity
06
Interacting drugs
Neutralizing antibodies
2 more in the full profile.
07
Biomarkers
Spike protein levels (viral load)Antibody titers against Spike proteinACE2 expression levels
Beyond the preview
Go deeper on SARS-CoV-2 Spike Glycoprotein (Omicron Variant) (Spike (Omicron)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 Spike Glycoprotein (Omicron Variant) (Spike (Omicron)).